TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06257030

Intervention type: DEVICE
Intervention: Transarterial Radioembolization
Description: (TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
Study: NCT06433245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
Study: NCT05558150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg
Study: NCT05718986

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06235476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplement
Description: Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixed plant-based protein supplement
Description: Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-health application
Description: Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric carbohydrate control
Description: Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
Study: NCT05467722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Single 12 mg oral dose administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Single 12 mg oral dose administered on Day 1
Study: NCT04497025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual-based vestibular rehabilitation
Description: Vestibular rehabilitation based on virtual environment using a head mounted display

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vestibular rehabilitation protocol
Description: Cawthorne-Cooksey vestibular rehabilitation exercises.
Study: NCT04812626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
Study: NCT04812652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally distributed yoga
Description: Yoga distributed through internet.
Study: NCT06539546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yttria stabilized multilayered (YML) zirconia restorations
Description: Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lithium disilicate restorations
Description: Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
Study: NCT06519123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Digital Scribes
Description: AI technology used to populate clinical notes.
Study: NCT06269107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IcoSema
Description: IcoSema will be administered subcutaneously.
Study: NCT06335056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProudMe
Description: ProudMe Tech: Regular human/computer interaction (3-5 times per week) to engage in SMART goal-setting, behavior monitoring, and self-reflection as assisted by AI-enabled feedback.~ProudMe Physical Education \[PE\]: 12 lessons to acquire knowledge, skill, and dispositions to improve physical activity, diet, screen-based sedentary behaviors.~ProudMe Cafeteria: Purposely enabling policy and environmental changes in school cafeteria (recognize areas of strengths and weaknesses; set goals and action plans; make changes to improve scores assessed by the Smarter Lunchroom Scorecard).~ProudMe Training: 4-hour implementation training + regular check-in and support (via motivational interviewing techniques)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the overall importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
Study: NCT06269107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine will be administered subcutaneously.
Study: NCT05204290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
Study: NCT04834869

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

Intervention type: BIOLOGICAL
Intervention: mRNA-1273
Description: Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

Intervention type: BIOLOGICAL
Intervention: AZD1222
Description: Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
Study: NCT05204290

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
Study: NCT06432764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Each participating patient will receive the study drug as specified in the study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ14132516
Description: A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination
Study: NCT04834869

Intervention type: BIOLOGICAL
Intervention: CoronaVac
Description: Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

Intervention type: BIOLOGICAL
Intervention: Sinopharm
Description: Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: Gam-COVID-Vac
Description: Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

Intervention type: BIOLOGICAL
Intervention: JNJ-78436735
Description: Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

Intervention type: BIOLOGICAL
Intervention: CVnCoV
Description: Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

Intervention type: BIOLOGICAL
Intervention: NVX-CoV2373
Description: Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

Intervention type: BIOLOGICAL
Intervention: BBV152
Description: Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
Study: NCT05321784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Description: Take digital dermoscopy images (DDI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photography
Description: Take smartphone clinical images (SCI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-Skin Examination
Description: Perform self-skin exam (SSE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Examination with Sklip
Description: Apply Sklip System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Examination
Description: Undergo in-person full body skin examination (FBSE)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06087835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan/Dapagliflozin
Description: Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized to
Study: NCT05902169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoCloud-9 (SC9)
Description: Implantation of SC9 device and repeat activation at constant acoustic pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Dosed and administered per labelling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Dosed and administered per labelling.
Study: NCT05022342

Intervention type: OTHER
Intervention: alpelisib plus fulvestrant
Description: Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
Study: NCT04915040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression
Description: Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate \& (b) gather feasibility data for home-based Behavioral Activation + Caregiver
Study: NCT06103903

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire according to age (6-13;14-17); the parents for minors and adults

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire according to age (6-13;14-17); the parents for minors and adults

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire according to age (6-13;14-17); the parents for minors and adults

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire according to age (6-13;14-17); the parents for minors and adults
Study: NCT06412874

Intervention type: OTHER
Intervention: Screening tool
Description: Participants will complete a screening tool survey
Study: NCT06375993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion
Study: NCT05346614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
Study: NCT06375993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion
Study: NCT05937672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
Description: The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
Study: NCT04521231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be administered as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be administered as a subcutaneous (SC) injection.
Study: NCT05192811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei K56
Description: probiotic K56 capsule, 1capsule/day (10\^9cfu) ,for 60days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule(maltodextrin) , 1capsule/day ,for 60days
Study: NCT04521231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be administered as a subcutaneous (SC) injection.
Study: NCT06378541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Hope Box Enhanced Facilitation
Description: The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will receive a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
Study: NCT05149521

Intervention type: OTHER
Intervention: None - this is a consensus group study to develop an intervention
Description: None - this is a consensus group study to develop an intervention
Study: NCT06378541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The EUC condition will involve a one-on-one, 30-minute session delivered prior to hospital discharge, during which the study interventionist will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).